Drugs / 27T51
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06469281 | Aug 2024 → May 2030 expected | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 27T51 | “This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug.” NCT06469281 ↗ |
| Modality | Cell therapy | “experimental CAR T cell therapy called 27T51” NCT06469281 ↗ |
| Target | MUC16 | “27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy” NCT06469281 ↗ |